Irish Food Stock News

ISE:KRZ
ISE:KRZFood

A Look At Kerry Group (ISE:KRZ) Valuation As The Board Lifts The Final 2025 Dividend

Kerry Group (ISE:KRZ) has put income on the agenda after the Board recommended a final dividend of €0.98 per share for 2025, representing a 10.1% increase on last year’s final payout. See our latest analysis for Kerry Group. The dividend news comes after a mixed period for the stock, with a recent 1-day share price return of 3.73% contrasted with a 30-day share price return decline of 7.93% and a 1-year total shareholder return decline of 28.44%, which suggests momentum has been fading...
ISE:GRP
ISE:GRPCapital Markets

Assessing Greencoat Renewables (ISE:GRP) Valuation After Its Recent 16.2% Monthly Share Price Gain

Why Greencoat Renewables Is On Investors’ Radar Greencoat Renewables (ISE:GRP) has drawn fresh attention after a strong month for the share price, with a 16.2% return. This has prompted investors to reassess how its wind focused portfolio and recent financial figures stack up. See our latest analysis for Greencoat Renewables. Despite a softer 1 day share price return of 1.16% and a 7 day share price return of 1.79%, the 30 day share price return of 16.16% and 1 year total shareholder return...
ISE:RYA
ISE:RYAAirlines

A Look At Ryanair Holdings (ISE:RYA) Valuation As It Expands Heavy Maintenance Capacity In Prestwick And Madrid

Ryanair Holdings (ISE:RYA) has put maintenance capacity firmly in the spotlight, committing £40 million to expand its Prestwick facility and €25 million to open a new Madrid Barajas maintenance centre, both tied to fleet and passenger growth plans. See our latest analysis for Ryanair Holdings. These heavy maintenance investments arrive after a softer run in the share price, with a 30 day share price return of an 8.22% decline and a year to date share price return of a 17.34% decline. Even...
ISE:KRZ
ISE:KRZFood

Kerry Group (ISE:KRZ) EPS Acceleration Reinforces Profit Growth Narrative Despite Flat 9.7% Margin

Kerry Group (ISE:KRZ) has released its FY 2025 numbers with second half revenue of €3.3b, basic EPS of €2.18 and net income of €355.4m, set against a trailing twelve month revenue base of €6.8b and EPS of €4.00. Over the past few periods, revenue has held in a tight range between €3.4b and €3.5b per half while basic EPS has moved from €1.55 in the first half of 2024 to €1.83 in the first half of 2025 and €2.18 in the second half of 2025, giving investors a clearer view of earnings power. With...
ISE:RYA
ISE:RYAAirlines

Ryanair Faces Austrian Bailiff Action While Shares Trade Below Analyst Targets

Austrian bailiffs boarded a Ryanair aircraft at Vienna airport to enforce an unpaid passenger compensation order. The action followed an Austrian court ruling that required Ryanair to pay compensation for a severely delayed flight. The aircraft was labeled for potential seizure as part of the enforcement process against Ryanair Holdings (ISE:RYA). Ryanair Holdings, trading at around €25.08, comes into this incident with a mixed recent share price record, including a 20.7% return over 1 year...
ISE:GL9
ISE:GL9Food

A Look At Glanbia (ISE:GL9) Valuation After Strong Recent Share Price Momentum

Glanbia (ISE:GL9) has drawn investor attention after its recent share performance, with the stock showing positive returns over the past month and past 3 months, prompting fresh interest in its €3,946.4m revenue nutrition-focused business. See our latest analysis for Glanbia. At a share price of €17.62, Glanbia’s recent 21.7% year to date share price return and 74.2% one year total shareholder return point to strong momentum that builds on its performance in sports and nutrition brands. If...
ISE:BIRG
ISE:BIRGBanks

A Look At Bank Of Ireland (ISE:BIRG) Valuation After Buyback Plan And Higher Proposed Dividend

Bank of Ireland Group (ISE:BIRG) has drawn fresh attention after announcing a proposed 2025 final dividend of €0.45 per share and a €530 million share buyback, released alongside its latest full year earnings report. See our latest analysis for Bank of Ireland Group. At a share price of €15.235, Bank of Ireland Group has seen a 1-year total shareholder return of 32.36%, while the 30-day share price return of 10.33% and year-to-date share price return of 8.83% suggest some recent momentum has...
ISE:GL9
ISE:GL9Food

Glanbia (ISE:GL9) One Off US$122.8M Loss Tests Bullish Growth Narrative

Glanbia (ISE:GL9) has reported its FY 2025 results with second half revenue of US$2.0 billion and basic EPS of US$0.34, alongside net income of US$83.9 million, putting fresh numbers behind the current share price of €17.25. The company has seen half year revenue move from US$2.02 billion with EPS of US$0.08 in 2024 H2 to US$1.93 billion and US$0.39 in 2025 H1, before landing at US$2.0 billion and US$0.34 in 2025 H2. This sets up a picture where margin trends and earnings quality are front of...
ISE:KRX
ISE:KRXBuilding

Assessing Kingspan Group’s (ISE:KRX) Valuation After Full-Year Earnings And Roofing Expansion

Why Kingspan Group’s latest earnings are on investors’ radar Kingspan Group (ISE:KRX) has attracted fresh attention after reporting full year 2025 earnings, with sales of €9,199 million and net income of €671.2 million, alongside progress in emissions reduction and US roofing expansion. See our latest analysis for Kingspan Group. The earnings release appears to have reset expectations, with the 1-day share price return of 7.72% lifting Kingspan to €85.8. A 30-day share price return of 18.92%...
ISE:IRES
ISE:IRESResidential REITs

European Small Caps With Insider Action Highlighting Undervalued Opportunities

As the pan-European STOXX Europe 600 Index reaches new heights, buoyed by an improving economic backdrop and marking its strongest yearly performance since 2021, investors are increasingly focusing on small-cap opportunities within this dynamic market landscape. In such a thriving environment, identifying stocks with strong fundamentals and insider activity can highlight potential undervalued opportunities in the European small-cap sector.
ISE:UPR
ISE:UPRHealthcare

Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?

Zevra Therapeutics announced that it has entered into an exclusive expanded access distribution agreement with Ireland-based Uniphar, enabling Niemann-Pick Disease Type C patients in select territories outside Europe to obtain reimbursed named-patient supply of MIPLYFFA, the only approved therapy that targets the underlying pathology of this ultra-rare condition. The deal strengthens Uniphar’s position as a specialist partner for complex rare-disease logistics, highlighting its capabilities...